Optic nerve glioma
|Optic nerve glioma|
|Magnetic resonance image of a large retrobulbar optic nerve tumor causing massive proptosis|
Optic gliomas are usually pilocytic tumors, and can involve the optic nerve or optic chiasm. Optic gliomas are usually associated with neurofibromatosis type 1 in 30% of people with the condition.
Optic nerve gliomas are diagnosed using magnetic resonance imaging (MRI) and CT scans. The tumor adopts a fusiform appearance, appearing wider in the middle and tapered at the ends. Enlargement of the optic nerve along with a downward kink in the mid-orbit is usually observed. While CT scans allow for optic nerve evaluation, MRI allows for intracranial evaluation to observe if the tumor has extended to other regions such as the optic chiasm & hypothalamus.
The main goal of treating optic gliomas is to preserve vision for as long as possible. The tumor’s slow & self-limiting growth indicates that it is not immediately problematic in most benign cases, with long-term studies showing that people with optic glioma may still have stable functional vision without intervention. As a result, the first & preferred course of action is usually observation of optic glioma over time.
Once the first signs of visual deterioration and/or tumor progression are observed, interventional treatments will then commence. These include radiation therapy, [[chemotherapy and surgical excision. While being the most effective therapy, radiation has shown damaging effects on the already compromised intellect as well as an increase in vascular issues & second tumor formation in children with neurofibromatosis 1. However, fractionated stereotactic radiation therapy (FSRT) is gaining traction as the most preferred interventional treatment for optic nerve glioma due to its combination of the therapeutic efficiency of radiation therapy without the negative side effects. Chemotherapy has also been shown to be a safer alternative to most radiation therapies & surgery for very young children (under the age of 3). However, the optimal chemotherapeutic therapy has not been defined, with risks of different toxicities still observed in older children. Surgery is considered the final choice of treatment, due to the high risk of blindness & damage to the affected eye. It is considered in only certain scenarios, such as relieving a cosmetically unappealing bulging eye (exophthalmos), removing an enlarging and/or expanding tumor or a combination of both.
Optic gliomas alternate between periods of inactivity and growth, making their clinical presentation variable & clinical course unpredictable. Once the optic chiasm is involved, the prognosis for life & vision worsens.
- Huson, Susan Mary; Hughes, Richard Anthony Cranmer (1994). The neurofibromatoses: a pathogenetic and clinical overview. London: Chapman & Hall. 1.3.2:9. ISBN 0-412-38920-7.
- Skelley, Tao Le, Vikas Bhushan, Nathan William (2012-03-12). First aid for the USMLE step 2 CK (8th ed.). New York: McGraw-Hill Medical. ISBN 978-0-07-176137-6.
- Goldman, Lee. Goldman's Cecil Medicine (24th ed.). Philadelphia: Elsevier Saunders. p. 1251. ISBN 1437727883.
- Cameron, JD; Rodriguez, FJ; Rushing, E; Horkayne-Szakaly, I; Eberhart, C (2014). "An 80-year experience with optic nerve glioma cases at the Armed Forces Institute of Pathology: evolution from museum to molecular evaluation suggests possibe interventions in the cellular senescence and microglial pathways (an American Ophthalmological Society thesis)". Transactions of the American Ophthalmological Society. 112: 11–25. PMID 25411512.
- Shapey, J.; Danesh-Meyer, H.V.; Kaye, A.H. (December 2011). "Diagnosis and management of optic nerve glioma". Journal of Clinical Neuroscience. 18 (12): 1585–1591. doi:10.1016/j.jocn.2011.09.003.
- Nair, Akshay Gopinathan; Pathak, Rima S.; Iyer, Veena R.; Gandhi, Rashmin A. (16 April 2014). "Optic nerve glioma: an update". International Ophthalmology. 34 (4): 999–1005. doi:10.1007/s10792-014-9942-8.
- Miller, NR (November 2004). "Primary tumours of the optic nerve and its sheath". Eye (London, England). 18 (11): 1026–37. doi:10.1038/sj.eye.6701592. PMID 15534587.